Loading
Life sciences · Observational Study
ClinicalTrials.gov · October 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Observational Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06483997). This is a study registration, not published results. Lead sponsor: George Washington University. Recruitment status: ACTIVE_NOT_RECRUITING. Study type: OBSERVATIONAL. Enrollment: 100 participants (ESTIMATED). Conditions: Breast Cancer Female, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Endometrial Cancer, Gynecologic Cancer. Primary outcome measures: Serum hepcidin concentration , pre-chemotherapy, single measure; Chemotherapy relative dose intensity , during chemotherapy (up to 6 months, depends on duration of chemotherapy regimen), represents repeated measures. Brief summary: This prospective, observational cohort study will evaluate the extent of associations between self-reported pro- or anti- inflammatory dietary intake patterns for one month before induction chemotherapy for gynecological cancer or neo/adjuvant chemotherapy for breast cancer and baseline serum hepcidin concentrations. Associations between hepcidin concentration and relative dose intensity (RDI) of chemotherapy will also be evaluated.